Literature DB >> 17761121

Advances in the management of gastroparesis.

Frank K Friedenberg1, Henry P Parkman.   

Abstract

The treatment goals for patients with gastroparesis are to control symptoms; to correct fluid, electrolyte, and nutritional deficiencies; and to identify and treat the underlying cause of gastroparesis. For mild symptoms, dietary modifications and a low-dose antiemetic and/or prokinetic agent might provide satisfactory control of symptoms. Dietary treatments include decreasing the solid food component while increasing the liquid nutrient component of meals. Fat and fiber intake should be minimized. Metoclopramide, despite its potential for neurological side effects, remains a prokinetic treatment for symptomatic patients. In patients with diabetic gastroparesis, careful regulation of glycemic control may help to reduce symptoms. Medical management of patients with gastroparesis who do not respond to initial antiemetic or prokinetic therapy or who develop medication-related side effects involves the use of other prokinetic and antiemetic agents with different mechanisms of action. Combinations of prokinetic and antiemetic agents often are tried in patients with persistent symptoms. In some patients with persistent refractory symptoms and failure to maintain adequate fluid and/or nutritional intake, bypassing the stomach with jejunostomy feedings may be necessary. Gastric electrical stimulation is a treatment for refractory gastroparesis. Based on initial studies showing symptom benefit, especially in patients with diabetic gastroparesis, gastric electrical stimulation was granted humanitarian US Food and Drug Administration approval for the treatment of chronic, refractory nausea and vomiting secondary to idiopathic or diabetic gastroparesis. However, which patients are likely to respond, the optimal electrode position, and the optimal stimulation parameters remain areas that need to be addressed.

Entities:  

Year:  2007        PMID: 17761121     DOI: 10.1007/s11938-007-0071-6

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  31 in total

Review 1.  The use of botulinum toxin for the treatment of gastrointestinal motility disorders.

Authors:  Frank Friedenberg; Satya Gollamudi; Henry P Parkman
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

2.  Evaluation of an inexpensive screening scintigraphic test of gastric emptying.

Authors:  G M Thomforde; M Camilleri; S F Phillips; L A Forstrom
Journal:  J Nucl Med       Date:  1995-01       Impact factor: 10.057

3.  Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes.

Authors:  C L He; E E Soffer; C D Ferris; R M Walsh; J H Szurszewski; G Farrugia
Journal:  Gastroenterology       Date:  2001-08       Impact factor: 22.682

4.  Assessment of gastric emptying using a low fat meal: establishment of international control values.

Authors:  G Tougas; E Y Eaker; T L Abell; H Abrahamsson; M Boivin; J Chen; M P Hocking; E M Quigley; K L Koch; A Z Tokayer; V Stanghellini; Y Chen; J D Huizinga; J Rydén; I Bourgeois; R W McCallum
Journal:  Am J Gastroenterol       Date:  2000-06       Impact factor: 10.864

5.  Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one center's experience.

Authors:  J K DiBaise; E M Quigley
Journal:  J Clin Gastroenterol       Date:  1999-03       Impact factor: 3.062

6.  Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review.

Authors:  R J Fontana; J L Barnett
Journal:  Am J Gastroenterol       Date:  1996-10       Impact factor: 10.864

7.  Treatment of diabetic gastroparesis with oral clonidine.

Authors:  L Rosa-e-Silva; L E Troncon; R B Oliveira; N Iazigi; L Gallo; M C Foss
Journal:  Aliment Pharmacol Ther       Date:  1995-04       Impact factor: 8.171

Review 8.  Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.

Authors:  L G Miller; J Jankovic
Journal:  Arch Intern Med       Date:  1989-11

9.  A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis.

Authors:  R W McCallum; D A Ricci; H Rakatansky; J Behar; J B Rhodes; G Salen; J Deren; A Ippoliti; H W Olsen; K Falchuk
Journal:  Diabetes Care       Date:  1983 Sep-Oct       Impact factor: 19.112

10.  The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.

Authors:  L Ganzini; D E Casey; W F Hoffman; A L McCall
Journal:  Arch Intern Med       Date:  1993-06-28
View more
  4 in total

1.  Treatment of dysautonomia in extrapyramidal disorders.

Authors:  Tjalf Ziemssen; Heinz Reichmann
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

Review 2.  Endoscopic treatment of gastroparesis.

Authors:  Thomas R McCarty; Tarun Rustagi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 3.  Treatment of dysautonomia in extrapyramidal disorders.

Authors:  Tjalf Ziemssen; Gerd Fuchs; Wolfgang Greulich; Heinz Reichmann; Michael Schwarz; Birgit Herting
Journal:  J Neurol       Date:  2011-05       Impact factor: 4.849

4.  Quality of life and symptomatic response to gastric neurostimulation for gastroparesis.

Authors:  Vic Velanovich
Journal:  J Gastrointest Surg       Date:  2008-08-20       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.